Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Frequently asked questions
What sector does LAKEFRONT BIOTHERAPEUTICS NV (LKFT) operate in?
LAKEFRONT BIOTHERAPEUTICS NV belongs to the Other sector and operates in the Biotechnology industry.
What is LAKEFRONT BIOTHERAPEUTICS NV (LKFT) current stock price?
As of the latest data, LAKEFRONT BIOTHERAPEUTICS NV stock price is €24.30, with a previous close of €24.44. LAKEFRONT BIOTHERAPEUTICS NV lost -€0.14 in the last trading session, representing a -0.57% loss.
What is LAKEFRONT BIOTHERAPEUTICS NV (LKFT) current market capitalization?
LAKEFRONT BIOTHERAPEUTICS NV market cap is approximately 1.59 billion.
What is LAKEFRONT BIOTHERAPEUTICS NV (LKFT) Earnings Per Share (EPS)?
The trailing EPS is €7.41, and the forward EPS is -€3.91.
What is LAKEFRONT BIOTHERAPEUTICS NV (LKFT) Price-to-Earnings (P/E) ratio?
LAKEFRONT BIOTHERAPEUTICS NV current P/E ratio is 3.28.
What is LAKEFRONT BIOTHERAPEUTICS NV (LKFT) EBITDA?
LAKEFRONT BIOTHERAPEUTICS NV EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -64.78 million.
Does LAKEFRONT BIOTHERAPEUTICS NV (LKFT) pay dividends?
No. LAKEFRONT BIOTHERAPEUTICS NV does not pay a dividend.
When is LAKEFRONT BIOTHERAPEUTICS NV (LKFT) next earnings report?
LAKEFRONT BIOTHERAPEUTICS NV is expected to release its next earnings report on June 30, 2026.
What is LAKEFRONT BIOTHERAPEUTICS NV (LKFT) beta (volatility) score?
LAKEFRONT BIOTHERAPEUTICS NV has a beta of 0.112, indicating lower volatility than the overall market.
